REGN Q3 Earnings: Will Higher Dupixent Profits Offset Eylea Sales Decline?

Core Insights - Investors are focusing on profits from asthma drug Dupixent and sales of Eylea HD as Regeneron Pharmaceuticals prepares to report its third-quarter 2025 results on October 28, 2025, with revenue estimates at $3.60 billion and earnings at $9.54 per share [1] Financial Performance - Regeneron has a history of earnings surprises, beating estimates in three of the last four quarters with an average surprise of 16.99%, including a 60.52% beat in the last reported quarter [2] - The Earnings ESP for Regeneron is -0.63%, indicating a potential earnings miss, with the Zacks Consensus Estimate at $9.54 per share and the Most Accurate Estimate at $9.48 [4] Product Sales - Eylea, a significant revenue source for Regeneron, has faced declining sales due to competition from Vabysmo, with U.S. sales estimated at $686 million for Q3 [6] - Eylea HD, a higher dose version, is expected to see strong sales, estimated at $414 million, potentially offsetting declines in Eylea sales [7] - Dupixent sales are projected to rise by 26.2% in Q3, driven by strong demand across multiple approved indications, contributing to Regeneron's profits [9] Oncology Franchise - Regeneron is diversifying its revenue base to reduce dependence on Eylea, with growth in its oncology franchise driven by Libtayo and the newly approved Lynozyfic [10][12] - Libtayo sales are estimated at $370 million, benefiting from increased demand for non-melanoma skin indications [11] Operating Expenses and Share Buybacks - Operating expenses are likely to have increased due to pipeline advancements and commercialization efforts for Eylea HD [13] - A decrease in outstanding shares from a $3.0 billion share repurchase program may positively impact the bottom line [14] Regulatory Updates - Investors will be looking for updates on key pipeline and regulatory developments, including the recent FDA approval for Libtayo's label expansion [15] Stock Performance - Regeneron's shares have declined by 18.8% year-to-date, contrasting with the industry's growth of 11.1% [16]